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Abstract: The mechanisms that regulate the systemic extent of atherosclerosis are not fully under-
stood. We investigated whether the expression of circulating miRNAs is associated with the extent of
stable atherosclerosis to a single territory or multiple territories (polyvascular) and with the sever-
ity of atherosclerosis in each territory. Ninety-four participants were prospectively recruited and
divided into five age- and sex-matched groups: presenting no atherosclerosis, isolated coronary
atherosclerosis, coronary and lower extremity atherosclerosis, coronary and carotid atherosclerosis,
and atherosclerosis of the coronary, lower extremity, and carotid territories. The expression of six
circulating miRNAs with distinct biological roles was assessed. The expression of miR-27b and
miR-146 differed across groups (p < 0.05), showing a decrease in the presence of atherosclerosis,
particularly in the three territories. miR-27b and miR-146 expression decreased in association with a
higher severity of coronary, lower extremity, and carotid atherosclerosis. Polyvascular atherosclerosis
involving the three territories was independently associated with a decreased miR-27b and miR-146
expression. Both miRNAs presented an area under the curve of ≥0.75 for predicting polyvascular
atherosclerosis involving the three territories. To conclude, miR-27b and miR-146 were associated
with the presence of severe polyvascular atherosclerosis and with the atherosclerosis severity in each
territory. Both are potential biomarkers of severe systemic atherosclerosis.
Keywords: atherosclerosis; carotid artery disease; coronary artery disease; lower extremity arterial
disease; miRNA; miR-27b; miR-146
1. Introduction
The mechanisms that regulate the extent of atherosclerosis in a single territory or
multiple territories (polyvascular), and the severity of atherosclerosis in each territory, are
not fully understood [1,2]. Acquired cardiovascular risk factors and genetic Mendelian in-
heritance explain only partially the heterogeneity of the systemic extent of stable atheroscle-
rosis [2,3]. Epigenetic mediators, such as miRNAs, which regulate genetic expression at
the post-transcriptional level, may contribute to such heterogeneity [4].
The role of several miRNAs in the regulation of different biological pathways involved
in atherosclerosis development and progression have been described using preclinical
models [4]. Altered expression of different circulating miRNAs in the presence of stable
atherosclerosis of specific territories has been identified in humans [5]. However, to the best
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of our knowledge, there are no published data on the relationship between the expression
of circulating miRNAs and the extent of stable atherosclerosis in multiple territories with a
systematic screening of atherosclerosis in different territories. Polyvascular atherosclerosis
warrants special attention not only because it may have a pathophysiology different from
that of single-vascular atherosclerosis, but also because it is frequently encountered in
clinical practice and is associated with a higher risk of ischemic events [6,7]. Knowledge
on the miRNA expression profile in polyvascular atherosclerosis may provide insights
into its phenotype, and therefore, its pathophysiology, since the biological role of several
miRNAs has been identified in vitro [4]. Moreover, investigating a potential signature
of circulating miRNAs in polyvascular atherosclerosis may be useful for clinical practice
as it could contribute to identifying simple non-invasive diagnostic biomarkers for the
stratification of systemic atherosclerotic burden [4].
The principal aim of this study was to determine whether the expression of circulating
miRNAs is associated with the extent of stable atherosclerosis in a single-vascular or
polyvascular disease. We also investigated whether the expression of circulating miRNAs
is associated with atherosclerosis severity in each territory. We hypothesized that the
miRNA expression profile is associated with the systemic extent of atherosclerosis in
multiple territories and the severity of atherosclerosis in each territory.
2. Materials and Methods
This study is a part of a project aimed at assessing the mechanisms underlying the
expression of stable atherosclerosis as a single-vascular (coronary) or polyvascular (coro-
nary, lower extremity, and/or carotid) disease. The study protocol was approved by the
ethics committees of the involved institutions (Centro Hospitalar Universitário de Lisboa
Central, Nr. 245/2015, in 2015, and NOVA Medical School, Faculdade de Ciências Médicas,
Universidade NOVA de Lisboa, Nr. 000176, in 2015). The investigation conformed to
the principles outlined in the Helsinki Declaration. All the participants signed informed
consent forms.
2.1. Recruitment of Participants
To assess the expression levels of circulating miRNAs in single-vascular and polyvas-
cular atherosclerosis, we prospectively recruited five groups of age- and sex-matched partic-
ipants from our center: control, with no coronary, lower extremity, or carotid atherosclerosis;
group 1, with isolated coronary atherosclerosis; group 2, with coronary and lower extrem-
ity atherosclerosis; group 3, with coronary and carotid atherosclerosis; and group 4, with
atherosclerosis of the coronary, lower extremity, and carotid territories. All the participants
were screened for obstructive atherosclerotic disease in the three territories.
Coronary artery disease was excluded in control participants if they presented no
effort angina; no evidence of coronary atherosclerosis on coronary computed tomography
angiography (64-slice computed tomography scanner LightSpeed VCT XT, GE Healthcare,
Milwaukee, WI, USA), including a calcium score of 0 and no soft plaques; and no positive
myocardial stress test (the latter was not mandated to be assessed as per protocol). In
other participants, coronary artery disease was defined as luminal stenosis of at least 50%
for the left main artery or at least 70% for other epicardial vessels on invasive coronary
angiography. Lower extremity arterial disease was defined as a significant (≥50%) stenosis
on Doppler ultrasound at rest [8,9] or the combination of chronic claudication and an
ankle–brachial index equal to or less than 0.9 [9,10]. Doppler ultrasound was performed for
the characterization of lower extremity arterial disease. Carotid artery disease was defined
as a stenosis of at least 50% on Doppler ultrasound [9,10]. All Doppler ultrasound studies
of the lower extremity and carotid arteries were performed according to a standardized
protocol, using the Logiq S7 Expert Ultrasound System (GE Healthcare, Wauwatosa, WI,
USA), and measurements were performed while following published guidelines [9–11].
The exclusion criteria were as follows: patients with acute ischemic events within
12 months, either coronary, lower extremity, or cerebrovascular events; those with coronary
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artery bypass grafting or lower extremity bypass surgery performed within 12 months;
those with prior carotid endarterectomy or prior percutaneous intervention of the coronary,
lower extremity, or carotid arteries; those with critical limb ischemia (with ischemic rest
pain), heart failure, hemodynamically significant valvular heart disease, hematological
disorders, active infection, history of malignancy, chronic kidney disease (stage 4 or 5), or
severe hepatic dysfunction; those under 18 years of age; and those unable or unwilling to
consent to study participation.
2.2. Sample Size
No previous studies reported data on circulating miRNAs in both single-vascular
and polyvascular atherosclerosis with the systematic screening of atherosclerotic lesions in
different territories, which would be valuable for supporting the sample size estimation
in our study. In this pilot study, we planned to recruit at least 20 control participants,
20 patients with isolated coronary atherosclerosis (group 1), and 40 patients with coronary
and extra-coronary atherosclerosis (groups 2 to 4), including at least 10 patients per group in
groups 2 to 4. The recruitment of participants for each group continued even after meeting
the minimum number of participants until the minimum sample size was achieved for
all groups.
2.3. Data Collection
Data were collected prospectively after patient inclusion. A standardized record
of clinical, demographic, laboratory, echocardiographic, Doppler ultrasound, computed
tomography angiography, and invasive coronary angiography data was obtained from
each participant.
To evaluate the severity of coronary atherosclerosis, the following parameters were
assessed, based on invasive coronary angiography: the number of vessels with obstructive
disease (the left main artery, left anterior descending artery, circumflex artery, and right
coronary artery were scored separately, with a total score ranging from 0 to 4), the number
of coronary artery lesions, and the synergy between percutaneous coronary intervention
with taxus and cardiac surgery (SYNTAX) score [12], using acknowledged methods [12,13].
To evaluate the severity of lower extremity atherosclerosis, the number of arterial seg-
ments with obstructive disease on both sides was assessed, including the external iliac,
common femoral, superficial femoral, popliteal, anterior tibial, posterior tibial, and fibular
arteries [9,14]. The number of affected carotid sides was assessed.
2.4. Candidate miRNAs
Six candidate miRNAs (miR-21, miR-27b, miR-29a, miR-126, miR-146, and miR-218),
each playing a distinct biological role associated with the regulation of atherosclerosis devel-
opment and expression, were selected [4,13,14]. Among other functions, miR-21 regulates
vascular smooth cell and endothelial cell functions; miR-27b regulates lipid metabolism,
development of lipid-induced atherosclerotic lesions, and inflammatory pathways; miR-
29a regulates fibrosis and extracellular matrix composition; miR-126 regulates endothelial
function in response to shear stress; miR-146 regulates endothelial function in response to
inflammatory cytokines; and miR-218 regulates endothelial cell migration [4,15,16].
2.5. Quantification of Expression Levels of Candidate miRNAs
Peripheral blood was collected early in the morning under fasting conditions. Serum
was separated by centrifugation (500× g for 10 min) within 15 min of sampling. Aliquots
were stored at −80 ◦C and samples were thawed only once.
Total RNA was extracted from serum samples using the miRCURY™ RNA Isolation
Kit (Qiagen, Hilden, Germany). Complementary DNA was synthesized from total RNA
using the Universal cDNA synthesis kit from miRCURY™ LNA miRNA system (Qiagen,
Hilden, Germany). MiRNA amplification was performed using quantitative reverse-
transcription polymerase chain reaction (using the miRCURY™ LNA SYBR Green PCR
Diagnostics 2021, 11, 318 4 of 13
Kit and LNA™ PCR primers, Qiagen, Hilden, Germany), and the melting curve was
determined according to the following conditions: 95 ◦C for 10 min followed by 45 cycles
of 95 ◦C for 10 s and 60 ◦C for 60 s. All the reactions were performed in triplicates.
The amplification data were assessed using DataAssist™ Software v3.01 (Thermo Fisher
Scientific, Waltham, MA, USA). Cycle threshold (Ct) values greater than 40 were considered
undetermined [17–20]. The relative expression levels of the six candidate miRNAs were
calculated using the delta Ct (∆Ct) method, normalizing for the UniSp6 RNA spike-in
control [20–23]. Higher ∆Ct miRs represent lower circulating levels of the candidate
miRNAs [20–23].
2.6. Statistical Analysis
Discrete variables are presented as frequencies (percentages) and continuous variables
are presented as the mean (standard deviation) in normally distributed data or median
(interquartile range (IQR)) in variables without a normal distribution (Shapiro–Wilk test).
Categorical variables were analyzed using the chi-square or Fisher’s exact tests. Contin-
uous variables were analyzed using Student’s t-test or the Mann–Whitney test when the
normality was not verified. Comparisons between multiple groups were performed using
the analysis of variance (ANOVA) for normally distributed data and Kruskal–Wallis test
for variables without a normal distribution; the Bonferroni post hoc correction was used for
multiple pairwise comparisons. Pearson’s correlation was used to test correlations between
continuous variables. Multivariate linear regression analysis was performed using all clini-
cal, laboratory, and atherosclerosis data (including the systemic extent of atherosclerosis,
severity of atherosclerosis in different territories, and prior revascularization) as indepen-
dent variables, and ∆Ct miR-27b and ∆Ct miR-146 as dependent variables. Variables with
a p-value of <0.10 in the univariate analysis were tested in the multivariate model, with
a correction for collinearity. The areas under the receiver operating characteristic (ROC)
curves of ∆Ct miR-27b and ∆Ct miR-146 for predicting severe polyvascular atherosclerosis
(involving the three territories) were assessed. The level of significance was set at α = 0.05.
Analyses were conducted using SPSS software, version 26.0 (IBM Corp, Armonk, NY, USA).
3. Results
3.1. Clinical Characteristics, Laboratory Results, and Atherosclerosis Data of Participants
Ninety-four participants were included: 26 control participants, 20 with isolated
coronary atherosclerosis (group 1), 18 with coronary and lower extremity atherosclerosis
(group 2), 12 with coronary and carotid atherosclerosis (group 3), and 18 with atheroscle-
rosis of the coronary, lower extremity, and carotid territories (group 4). The clinical char-
acteristics, laboratory results, and atherosclerosis data of the participants are presented
in Table 1. The differences in clinical characteristics and laboratory data across groups
were driven by controls, which showed a lower prevalence of classical cardiovascular risk
factors and use of antiplatelet and statin therapy, and lower neutrophil count and creatinine
levels. Globally, the distribution of clinical and laboratory parameters did not differ among
groups 1 to 4. The severity of coronary atherosclerosis did not differ among groups 1 to 4,
including the number of diseased vessels, number of coronary lesions, and the SYNTAX
score (median 3, IQR 2–4; median 4, IQR 3–5; and mean 26.5 [9.3], respectively, among all
patients with coronary atherosclerosis). The number of lower extremity lesions was higher
in group 4 than in group 2 (median 3, IQR 2–5, among all patients with lower extremity
atherosclerosis). Among the patients with carotid atherosclerosis, 37% had bilateral disease,
and this rate did not differ between groups 3 and 4.
3.2. Expression of Circulating miRNAs According to the Systemic Extent of Atherosclerosis
The expression levels (∆Ct) of miR-27b and miR-146 differed across groups (ANOVA
p < 0.05 for both miRNAs; Table 2), whereas the expression levels of other miRNAs did not.
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Table 1. Characteristics of the participants according to the involved territories of atherosclerosis.
Study Group Control Group 1 Group 2 Group 3 Group 4 p-Value
Territories of atherosclerosis None Coronary Coronary + LE Coronary + Carotid Coronary + LE + Carotid
n 26 20 18 12 18
Clinical Characteristics
Age, years 59 (53–69) 65 (56–70) 67 (57–72) 59 (51–73) 69 (60–75) 0.079
Male, n (%) 23 (88.5) 18 (90.0) 16 (88.9) 10 (83.3) 17 (94.4) 0.912
Hypertension, n (%) 14 (53.8) 17 (85.0) a 18 (100.0) a 11 (91.7) a 18 (100.0) a <0.001
SBP, mmHg 132 (14) 130 (20) 133 (21) 135 (21) 130 (18) 0.939
DBP, mmHg 73 (10) 72 (11) 72 (11) 73 (12) 65 (9) 0.175
Dyslipidemia, n (%) 18 (69.2) 19 (95.0) a 18 (100.0) a 11 (91.7) 17 (94.4) a 0.010
Diabetes mellitus, n (%) 3 (11.5) 6 (30.0) 8 (44.4) a 6 (50.0) a 9 (50.0) a 0.036
Smoking history, n (%) 6 (23.1) 9 (45.0) 12 (66.7) a 4 (33.3) 12 (66.7) a 0.014
LVEF > 50%, n (%) 26 (100.0) 20 (100.0) 18 (100.0) 12 (100.0) 18 (100.0) –
Antiplatelet therapy, n (%) 6 (23.1) 20 (100.0) a 17 (94.4) a 11 (91.7) a 18 (100) a <0.001
Statin therapy, n (%) 13 (50.0) 18 (90.0) a 16 (94.1) a 11 (91.7) a 16 (88.9) a 0.001
Laboratory Parameters
Hemoglobin, g/dL 13.9 (12.9–15.0) 14.53 (10.0–15.1) 14.1 (13.2–14.6) 12.0 (11.4–13.4) b 12.9 (12.1–14.2) 0.017
Leukocyte count, 109/L 6.4 (1.7) 7.4 (1.9) 7.3 (1.7) 7.5 (2.2) 8.1 (1.7) 0.080
Neutrophil count, 109/L 3.2 (2.5–4.8) 4.1 (3.4–5.2) 3.9 (3.4–4.8) 4.0 (3.4–6.7) 4.7 (3.6–6.0) a 0.043
Lymphocyte count, 109/L 1.9 (1.7–2.2) 2.1 (1.6–2.4) 2.1 (1.6–2.8) 1.7 (1.2–2.3) 2.2 (1.6–2.6) 0.401
Platelet count, 109/L 242 (191–274) 209 (176–269) 219 (195–264) 229 (137–251) 227 (203–263) 0.854
Fasting glycaemia, mg/dL 89 (80–98) 94 (86–129) 94 (83–125) 99 (84–157) 85 (75–123) 0.385
Percentage of glycosylated hemoglobin 5.6 (5.2–5.9) 5.9 (5.6–6.7) 5.9 (5.5–6.1) 5.8 (5.4–7.4) 5.9 (5.3–7.7) 0.185
Creatinine, mg/dL 0.8 (0.7–0.9) 0.9 (0.8–1.1) 0.8 (0.8–1.2) 0.9 (0.8–1.4) 1.1 (0.9–1.5) a 0.002
Total cholesterol, mg/dL 186 (51) 164 (38) 172 (50) 153 (50) 173 (49) 0.329
LDL-cholesterol, mg/dL 99 (77–141) 95.0 (71–120) 106 (83–120) 65 (56–132) 117 (82–142) 0.297
HDL-cholesterol, mg/dL 51 (44–58) 35 (31–41) a 35 (31–45) a 40 (27–44) a 40 (32–42) a <0.001
Triglycerides, mg/dL 106 (67–144) 142 (98–206) 115 (83–204) 100 (62–177) 117 (95–171) 0.423
C-reactive protein, mg/L 4.1 (2.0) 3.7 (1.4) 3.8 (1.1) 4.1 (2.3) 3.3 (2.0) 0.151
Coronary Artery Disease
Nr. of vessels with obstructive disease * 0 (0–0) 3 (2–3) a 3 (2–4) a 3 (3–3) a 3 (2–4) a <0.001
Nr. of lesions 0 (0–0) 4 (2–5) a 4 (3–5) a 4 (3–5) a 4 (3–5) a <0.001
SYNTAX score 0 (0–0) 23.3 (8.4) a 29.6 (9.9) a 25.3 (7.2) a 28.1 (10.6) a <0.001
Prior CABG, n (%) 0 (0.0) 7 (35.0) a 7 (38.9) a 6 (50.0) a 3 (16.7) a 0.002
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Table 1. Cont.
Study Group Control Group 1 Group 2 Group 3 Group 4 p-Value
Territories of atherosclerosis None Coronary Coronary + LE Coronary + Carotid Coronary + LE + Carotid
n 26 20 18 12 18
LE Arterial Disease
Bilateral disease, n (%) 0 (0.0) 0 (0.0) 10 (55.5) a,b,d,e 0 (0.0) 15 (83.3) a–d <0.001
Nr. of segments with obstructive disease 0 (0–0) 0 (0–0) 2 (1–4) a,b,d,e 0 (0–0) 4 (3–5) a–d <0.001
Prior bypass surgery, n (%) 0 (0.0) 0 (0.0) 2 (11.1) a,b,d 0 (0.0) 6 (33.3) a,b,d <0.001
Carotid Artery Disease
Bilateral disease, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 3 (25.0) a–c 8 (44.4) a–c <0.001
Categorical variables are expressed as frequency (percentage) and continuous variables as the mean (standard deviation) or median (interquartile range). CABG—coronary artery bypass grafting; DBP—diastolic
blood pressure; HDL—high-density lipoproteins; LDL—low-density lipoproteins; LE—lower extremity; LVEF—left ventricular ejection fraction; Nr.—number; SBP—systolic blood pressure; SYNTAX—synergy
between percutaneous coronary intervention with taxus and cardiac surgery. a p-value < 0.05 vs. controls; b p-value < 0.05 vs. group 1; c p-value < 0.05 vs. group 2; d p-value < 0.05 vs. group 3; e p-value < 0.05 vs.
group 4; * the left main artery, left anterior descending artery, circumflex artery, and right coronary artery were scored separately, with a total score ranging from 0 to 4.
Table 2. Expression of circulating miRNAs according to the involved territories of atherosclerosis.
Study Group Control Group 1 Group 2 Group 3 Group 4 p-Value
Territories of atherosclerosis None Coronary Coronary + LE Coronary + Carotid Coronary + LE + Carotid
miRNAs
miR-21 14.73 (4.63) 15.60 (4.22) 14.14 (4.41) 13.83 (5.06) 18.22 (4.01) 0.064
miR-27b 17.82 (3.43) 19.39 (4.06) 19.03 (4.37) 18.71 (5.45) 22.34 (3.93) a 0.041
miR-29a 20.90 (3.52) 21.09 (2.02) 20.67 (2.90) 20.99 (5.06) 23.50 (2.79) 0.121
miR-126 17.38 (15.12–21.89) 17.79 (14.99–22.88) 16.79 (15.57–22.74) 14.85 (13.36–21.34) 23.32 (17.88–24.86) 0.102
miR-146 18.06 (3.00) 19.63 (3.34) 19.43 (4.39) 18.76 (4.21) 22.20 (3.47) a 0.048
miR-218 22.63 (10.01–23.51) 23.15 (16.18–26.12) 22.63 (10.87–25.71) 22.67 (9.19–23.36) 24.70 (23.88–25.68) 0.744
Delta Ct (∆Ct) values are presented for each miRNA (higher ∆Ct values correspond to lower miRNA expression levels) and are expressed as the mean (standard deviation) or median (interquartile range).
LE—lower extremity. a p-value < 0.05 vs. controls.
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The ∆Ct values of both miRNAs showed a stepwise increase (corresponding to a
decrease in their expression levels) from control participants to patients with atherosclerosis
of one or two territories (groups 1–3), and further to patients with atherosclerosis of three
territories (group 4), with significant differences between the controls and patients with
atherosclerosis of three territories. The relative expression of miR-27b and miR-146 is
presented in Figure 1 [24].
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rosis. 
For miR-27b, miR-126, and miR-146, there was a weak positive correlation between 
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3.3. Expression of Circulating miRNAs According to the Atherosclerosis Severity in Different Territories
For both miR-27b and miR-146, there was a weak positive correlation between ∆Ct
miR and the number of coronary arteries with obstructive disease (r = 0.241, p = 0.043 for
miR-27b; and r = 0.242, p = 0.036 for miR-146), number of coronary artery lesions (r = 0.241,
p = 0.043 for miR-27b; and r = 0.289, p = 0.012 for miR-146), and the SYNTAX score (r = 0.286,
p = 0.019 for miR-27b; and r = 0.257, p = 0.037 for miR-146), indicating decreased expression
levels of both miRNAs with an increase in the severity of coronary atherosclerosis.
For miR-27b, miR-126, and miR-146, there was a weak positive correlation between
∆Ct miR and the number of obstructive lesions in the lower extremity (r = 0.320, p = 0.008
for miR-27b; r = 0.254, p = 0.043 for miR-126; and r = 0.352, p = 0.003 for miR-146), indicating
decreased expression levels of the three miRNAs with an increase in the severity of lower
extremity atherosclerosis.
∆Ct miR-27b showed a stepwise increase from individuals with no carotid ather scl -
rosis (18.6 [3.9]) to patients with unilateral disease (19.6 [5.9]), and further to patients with
bilateral disease (21.7 [4.9]), with a sig ificant difference between individuals wit no
carotid atherosclerosis and those with b (p = 0.030), corresponding to lower
expression levels of miR-27b in bilateral carotid atherosclerosis.
3.4. Atherosclerosis Severity and miR-27b and miR-146 Expression Levels in Multivariate Analysis
The univariate analysis assessing the parameters associated with ∆Ct miR-27b and
∆Ct miR-146 is presented in Supplementary Tables S1 and S2, respectively (Supplementary
Materials). In the multivariate linear regression analysis, the presence of polyvascular
atherosclerosis involving the coronary, lower extremity, and carotid territories, and indexes
of coronary artery disease severity were independently associated with ∆Ct miR-27b and
∆Ct miR-146 (Table 3), after adjusting for the clinical characteristics, laboratory results, and
other parameters of atherosclerosis severity.
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Table 3. Parameters associated with miR-27b and miR-146 expression levels in multivariate linear
regression analysis.
β 95% CI p-Value
∆Ct miR-27b
Coexistence of coronary, LE, and carotid atherosclerosis 3.41 0.55–6.27 0.020
SYNTAX score 0.072 0.001–0.143 0.049
∆Ct miR-146
Coexistence of coronary, LE, and carotid atherosclerosis 3.10 0.73–5.46 0.011
Number of coronary artery lesions 0.373 0.015–0.730 0.041
95% CI—95% confidence interval; LE—lower extremity; SYNTAX—synergy between percutaneous coronary
intervention with taxus and cardiac surgery.
3.5. miR-27b and miR-146 as Predictors of Polyvascular Atherosclerosis
∆Ct miR-27b and ∆Ct miR-146 provided areas under the ROC curve of 0.76 (95% con-
fidence interval [CI] 0.60–0.91, p = 0.004) and 0.75 (95% CI 0.59–0.91, p = 0.009), respectively,
for predicting polyvascular atherosclerosis with concomitant involvement of the coronary,
lower extremity, and carotid arteries (Figure 2). The cut-off (21.5) of ∆Ct miR-27b indicated
77% sensitivity and 72% specificity, and the cut-off (21.6) of ∆Ct miR-146 indicated 73%
sensitivity and 77% specificity for predicting polyvascular atherosclerosis with concomitant
involvement of the three territories.




Figure 2. Accuracy of miR-27b and miR-146 as predictors of polyvascular atherosclerosis. The receiver operating charac-
teristics curve is presented for (a) ΔCt miR-27b and (b) ΔCt miR-146, as predictors of polyvascular atherosclerosis involv-
ing the coronary, lower extremity, and carotid territories. The optimal cut-off for (a) ΔCt miR-27b was 21.5 and for (b) ΔCt 
miR-146 was 21.6, presenting a Youden’s index [25,26] of 0.49 and 0.50, respectively. 95% CI—95% confidence interval; 
AUC—area under the curve. 
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In this prospective study, four main findings stood out: lower expression levels of 
miR-27b and miR-146 were associated with an increase in the systemic extent of athero-
sclerosis to multiple territories; lower expression levels of miR-27b and miR-146 were as-
sociated with an increase in the atherosclerosis severity within different arterial territories; 
polyvascular atherosclerosis involving the coronary, lower extremity, and carotid territo-
ries was independently associated with the miR-27b and miR-146 expression levels; and 
both miR-27b and miR-146 were reasonably accurate in predicting severe polyvascular 
atherosclerosis involving the three territories. The observed association between circulat-
ing miRNAs and the severity of atherosclerosis, particularly its systemic extent, is dis-
cussed below, along with an overview of published data on miRNA profiles in polyvas-
cular atherosclerosis and potential clinical implications of the results. The roles of miR-
27b and miR-146 in the regulation of atherosclerosis in experimental studies and the asso-
ciations of both miRNAs with atherosclerosis expression in humans are also discussed. 
To the best of our knowledge, this is the first study assessing the circulating miRNA 
expression profile in single- and polyvascular atherosclerosis with a systematic screening 
of atherosclerotic lesions in three major territories of atherosclerosis. One study reported 
an altered miRNA expression profile based on the number of territories with manifesta-
tions of atherosclerosis [21]. However, in this study, patients had heart failure, which may 
have altered the expression levels of several miRNAs [21,27], and the definition of ather-
osclerotic manifestation included prior acute ischemic events or revascularization proce-
dures, without a systematic screening of atherosclerotic lesions in the corresponding ter-
ritory [21]. We observed that polyvascular atherosclerosis was associated with a specific 
miRNA expression profile, particularly in severe polyvascular atherosclerosis with sim-
ultaneous involvement of the coronary, lower extremity, and carotid territories. In such a 
Figure 2. Accuracy of miR-27b and miR-146 as predictors of polyvascular atherosclerosis. The receiver operating character-
istics curve is presented for (a) ∆Ct miR-27b and (b) ∆Ct miR-146, as predictors of polyvascular atherosclerosis involving
the coronary, lower extremity, and carotid territories. The optimal cut-off for (a) ∆Ct miR-27b was 21.5 and for (b) ∆Ct
miR-146 was 21.6, presenting a Youden’s index [25,26] of 0.49 and 0.50, respectively. 95% CI—95% confidence interval;
AUC—area under the curve.
4. Discussion
In this prospective study, four main findings stood out: lower expression levels of miR-
27b and miR-146 were associated with an increase in the systemic extent of atherosclerosis
to multiple territories; lower expression levels of miR-27b and miR-146 were associated
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with an increase in the atherosclerosis severity within different arterial territories; polyvas-
cular atherosclerosis involving the coronary, lower extremity, and carotid territories was
independently associated with the miR-27b and miR-146 expression levels; and both miR-
27b and miR-146 were reasonably accurate in predicting severe polyvascular atherosclerosis
involving the three territories. The observed association between circulating miRNAs and
the severity of atherosclerosis, particularly its systemic extent, is discussed below, along
with an overview of published data on miRNA profiles in polyvascular atherosclerosis
and potential clinical implications of the results. The roles of miR-27b and miR-146 in the
regulation of atherosclerosis in experimental studies and the associations of both miRNAs
with atherosclerosis expression in humans are also discussed.
To the best of our knowledge, this is the first study assessing the circulating miRNA
expression profile in single- and polyvascular atherosclerosis with a systematic screening
of atherosclerotic lesions in three major territories of atherosclerosis. One study reported
an altered miRNA expression profile based on the number of territories with manifes-
tations of atherosclerosis [21]. However, in this study, patients had heart failure, which
may have altered the expression levels of several miRNAs [21,27], and the definition of
atherosclerotic manifestation included prior acute ischemic events or revascularization
procedures, without a systematic screening of atherosclerotic lesions in the corresponding
territory [21]. We observed that polyvascular atherosclerosis was associated with a spe-
cific miRNA expression profile, particularly in severe polyvascular atherosclerosis with
simultaneous involvement of the coronary, lower extremity, and carotid territories. In
such a scenario, both the atheroprotective miR-27b and miR-146 were significantly down-
regulated. Consistently, the expression levels of these two miRNAs decreased with an
increase in the severity of atherosclerosis in different territories, as assessed by different
complementary indexes [9,12,28]. The systemic extent of atherosclerosis with involvement
of the three territories was a major determinant of miR-27b and miR-146 expression levels
in multivariate analysis. Moreover, miR-27b and miR-146 showed reasonable accuracy for
predicting severe systemic atherosclerosis with involvement of the three territories. The
results highlight miR-27b and miR-146 as potential biomarkers that can contribute to detect
polyvascular atherosclerosis non-invasively. Screening of polyvascular atherosclerosis
in daily clinical practice by assessing simultaneously different arterial territories using
currently available methods is potentially laborious [9,28]. Therefore, miR-27b and miR-146
may simplify the stratification of systemic atherosclerotic burden [9,28]. Considering the
high morbidity and risk of mortality associated with polyvascular atherosclerosis [6,7],
the identification of severe systemic atherosclerosis using a simple, non-invasive tool may
be clinically useful as it could facilitate an early intensification of the atheroprotective
regimens, such as antithrombotic and lipid-lowering therapies [29–33]. Further studies are
needed to confirm these hypotheses.
In experimental studies, complementary atheroprotective mechanisms of miR-27b
have been reported, including the prevention of atherosclerosis by suppression of lipopro-
tein lipase–induced lipid accumulation and inflammatory response in mice [34]; downreg-
ulation of the expression of key genes involved in lipid metabolism and mitigation of the
accumulation of lipids in circulation [35]; decrease in vascular inflammation by the suppres-
sion of pro-inflammatory factor release [36], including that of interleukin 17–induced mono-
cyte chemoattractant protein-1 [37], contributing to a decrease in monocyte–macrophage
activation [38]; and repression of repulsive semaphorins, thereby facilitating the forma-
tion of tight endothelial monolayers and stable vessels in response to shear stress [39].
miR-146 is induced in endothelial cells in response to pro-inflammatory cytokines and
acts as a negative feedback regulator of inflammatory signaling in endothelial cells by
dampening the activation of pro-inflammatory transcriptional programs, including the
NF-κB, AP-1, and MAPK/EGR pathways, and by promoting eNOS expression [4,15,40]. In
addition, the enhancement of miR-146a levels in monocytes and macrophages by cellular
apoE suppresses NF-κB-mediated inflammation and atherosclerosis [41]. Considering the
miR-27b and miR-146 dysregulation observed in our study and their specific biological
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roles described in the aforementioned experimental studies [4,15,16,34–41], the extent of
atherosclerosis in multiple territories and within each territory appears to be influenced by
lipid metabolism and lipid accumulation in the vessel, and by the inflammatory response
involving endothelial and monocyte–macrophage cells. These data reinforce the described
mechanistic role of miRNAs in coupling lipid metabolism, endothelial dysfunction, inflam-
mation, and atherosclerosis [42–46]. The interplay is complex, with each miRNA acting in
multiple pathways and in different steps of a specific pathway, as post-transcriptional hubs.
In humans, published data on miR-27b and miR-146 expression in the presence of
atherosclerosis are scarce. miR-27b was reported to be downregulated in the presence of
lower extremity atherosclerosis [47]. Although miR-146 has been reported to be upregu-
lated in patients with coronary atherosclerosis [48], which conflicts with the experimental
data [4,13,30], it was reported to be downregulated in more severe forms of coronary
atherosclerosis, including acute coronary syndromes, compared with stable coronary artery
disease [49], and coronary atherosclerosis associated with poor collateral circulation [50].
No data have been published on the expression levels of these two miRNAs in polyvascular
disease. As previously discussed, not only data from experimental studies but also studies
in humans support the downregulation of miR-27b and miR-146 in more severe forms of
atherosclerosis, including polyvascular atherosclerosis.
The strengths of this study should be acknowledged. To the best of our knowledge,
this is the first description of the expression profile of circulating miRNAs based on the
presence of single-vascular and polyvascular obstructive atherosclerosis. The prospective
nature of this study and the systematic screening of three major arterial territories have
contributed to the accuracy of our findings. The consistency of results was reinforced for
the following reasons: the multivariate analysis carried out confirmed the independent
association between polyvascular atherosclerosis and miR-27b and miR-146 expression;
analyses of the severity/extent of atherosclerosis within different territories showed a
similar direction of miR-27b and miR-146 dysregulation compared with the analyses of
the systemic extent of atherosclerosis (specifically, miR-27b and miR-146 downregulation
in more severe presentations of atherosclerosis); and the results are in line with data from
experimental studies and studies in patients with atherosclerosis [4,15,16,34–41,47,49,50].
This is the first report on the diagnostic accuracy of circulating miRNAs, including miR-
27b and miR-146, for the detection of severe polyvascular atherosclerosis. The results
have potential implications for a clinical condition that is frequent in clinical practice
and associated with considerable morbimortality, as both miRNAs may consist of simple
non-invasive tools for stratifying the systemic atherosclerotic burden.
Our study has some limitations. The sample may be of limited size. However, as
this study pioneered the investigation of the expression of circulating miRNAs in single-
vascular and polyvascular atherosclerosis with a systematic screening of atherosclerotic
lesions in different territories, no data were available to support the sample size estimation.
In this exploratory pilot study, the sample size was sufficient to analyze the miRNA
expression profile in such a clinical scenario, allowing to detect differences in the expression
levels of circulating miRNAs in polyvascular atherosclerosis. The atherosclerosis extent in
multiple territories and disease severity within each territory are commonly associated,
and both may influence miRNA expression levels [4,21,51], which could have been a
potential source of bias regarding the studied association between atherosclerosis extent
to multiple territories and miRNA expression. However, coronary artery disease, which
was the common factor to all patients, presented a well-balanced severity among the
different groups of patients. Moreover, the multivariate analysis confirmed an independent
association between the atherosclerosis extent in multiple territories and miRNA (miR-27b
and miR-146) expression levels, irrespective of disease severity within each territory. This
suggests that atherosclerosis severity within each territory may not have been a significant
source of bias. Of note, this is a single-center study, which may limit the applicability of
results to different clinical settings. Further multicentric studies performing an external
validation are warranted.
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5. Conclusions
Lower expression levels of atheroprotective miR-27b and miR-146 were associated
with the presence of severe polyvascular atherosclerosis and with higher severity of
atherosclerosis in different territories, including the coronary, lower extremity, and carotid
territories. The simultaneous involvement of the three territories was the most important
determinant of miR-27b and miR-146 dysregulation, and both miRNAs showed reasonable
accuracy for predicting polyvascular atherosclerosis affecting the three territories. Our
results provide insights into the pathophysiology of polyvascular atherosclerosis. In ad-
dition, miR-27b and miR-146 seem to be promising non-invasive biomarkers for refining
the stratification of systemic atherosclerotic burden and, therefore, may contribute to the
tailoring of primary prevention strategies.
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